Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...

While first-line EGFR inhibitors have revolutionized the treatment of mutant lung cancer, the inevitable development of ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...

In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...

In a recent study published in the journal Nature Biotechnology, researchers in Switzerland used base and prime editing to create and analyze a wide array of variants of the epithelial growth factor ...

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...

Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort. The study reported a median duration of response of 8.7 months and a ...

Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2024 ...

Global trends of early onset cancers (15-49 years) 1990-2021 and projection to 2040. Incidence and survival trends in adolescents and young adults with carcinoma of unknown primary: Insights from the ...